Corneal topography important to monitor after CXL

Article

When performing corneal collagen crosslinking (CXL), ophthalmologists should monitor the keratoconus index and the index of height asymmetry garnered from the Scheimpflug camera, because changes in values of these indices are independent from initial corneal thickness.

When performing corneal collagen crosslinking (CXL), ophthalmologists should monitor the keratoconus index and the index of height asymmetry garnered from the Scheimpflug camera, because changes in values of these indices are independent from initial corneal thickness. So say researchers from Hungary publishing their work in the Journal of Refractive Surgery.

The researchers, from Hungary, performed CXL in 25 eyes with progressive keratoconus; 25 fellow eyes with nonprogressive keratoconus were the control subjects. The Scheimpflug camera was used to measure thinnest corneal thickness, anterior keratometry (flat, steep) and keratoconus indices before and after CXL (at 12 to 25 months). They assessed the influence of corneal thickness and follow-up time on the flattening effect of CXL using regression analysis.

The investigators found that, at baseline, the eyes that had undergone CXL had significantly higher steep keratometric values and lower thinnest corneal thickness values. These findings were parallel with increased values of the following keratoconus indices: index of surface variance, index of vertical asymmetry, keratoconus index, centre keratoconus index, index of height asymmetry, index of height decentration and radius minimum.

After they adjusted for thinnest corneal thickness and follow-up time, the researchers found that a significant flattening effect was shown with CXL; it was expressed by changes in radius minimum, index of surface variance, keratoconus index, center keratoconus index and index of height asymmetry. Changes of index of surface variance, index of vertical asymmetry and center keratoconus index were significantly influenced by thinnest corneal thickness. Follow-up time had no significant influence in any of the models studied.

To read an abstract of the study, visit the journal's website.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.